Merck Sharp + Dohme Corp.

Merck Sharp & Dohme LLC

Brendan M Crowley

Ian M Bell

Andrew John Harvey

Brian T Campbell

Kenneth J Leavitt

Thomas J Greshock

Vanessa L Rada

David Brian Olsen

Philippe G Nantermet

Takao Suzuki

William D Shipe

Deodial Guy Guiadeen

Belinda C Huff

John M Sanders

Lihu Yang

Dharam Paul

Joseph Leslie Duffy

Christophe Morice

Lanying You

Christophe Joseph

Linda M Suen

Patrick Bazzini

Joseph A Kozlowski

Ling Tong

Anthony W Shaw

Deodial G Guiadeen

Daniel Vincent Paone

Christopher S Burgey

Izzat Tiedje Raheem

Peter J Manley

Jing Su

Harry R Chobanian

Bruno Giethlen

Anthony J Roecker

Marc A Labroli

Zhengwu James Deng

Rajinder Singh

Justin Ripper

Craig M Potteiger

Laurent Schaeffer

Jean-Marie Contreras

Thomas Avery

Fabrice Garrido

James I Fells

Deyou Sha

Joseph L Duffy

Randall R Miller

James Fells

Negxue Wang

Aurelie Witzel

Michael Aaron Plotkin

Andrew John Cooke

Aurelie Fromeyer

Philippe Nantermet

Christopher Douglas Cox

Richard Thaddeus Berger

Zhengwu J Deng

Jason W Skudlarek

The present invention relates to novel Bicyclic Heterocycle Compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein A, X, Y, Z, R1 R5, R6, and R7 are as defined herein. The present invention also relates to compositions comprising at least one Bicyclic Heterocycle Compound, and methods of using the Bicyclic Heterocycle Compounds for treating or preventing a herpesvirus infection in a patient.

Bicyclic heterocycle compounds methods of use thereof for the treatment of herpes viruses

Disclosed are dihydroisoxazole compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein A, E, and Rare as defined herein. Also disclosed are compositions which comprise at least one of these dihydroisoxazole compounds, methods for inhibiting growth of mycobacterial cells as well as a method of treating mycobacterial infections bycomprising administering a therapeutically effective amount of these dihydroisoxazole compounds and/or a pharmaceutically acceptable salt thereof, or a composition comprising such compound and/or salt.

Compounds and methods of use thereof as antibacterial agents

The present invention relates to the oxazolidinone compound of Formula (I): and pharmaceutically acceptable salts thereof. The present invention also relates to compositions containing the compound of Formula (I). The invention also provides methods for inhibiting growth of mycobacterial cells as well as a method of treating mycobacterial infections byby administering a therapeutically effective amount of Formula (I) and/or a pharmaceutically acceptable salt thereof, or a composition comprising such compound and/or salt.

Oxazolidinone compound and methods of use thereof as an antibacterial agent

The present invention discloses oxazolidinone compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A and E, are as defined herein. The present invention also relates to compositions which comprise at least one oxazolidinone compound of the invention. The invention also provides methods for inhibiting growth of mycobacterial cells as well as a method of treating mycobacterial infections bycomprising administering a therapeutically effective amount of an oxazolidinone of the invention and/or a pharmaceutically acceptable salt thereof, or a composition comprising such compound and/or salt.

Oxazolidinone compounds and methods of use thereof as antibacterial agents

The present disclosure relates to compounds of formula I that are useful as modulators of α7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation

Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors

The present disclosure relates to compounds of formula I that are useful as modulators of &#x3b1;7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation

Substituted 6-membered aryl or heteroaryl allosteric modulators of nicotinic acetylcholine receptors

The present disclosure relates to compounds of formula I that are useful as modulators of 7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation (I). 

Heteroaryl allosteric modulators of nicotinic acetylcholine receptors

The present disclosure relates to compounds of formula (I) that are useful as modulators of &#x3b1;7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation. 

Substituted bicyclic heteroaryl allosteric modulators of nicotinic acetylcholine receptors

Disclosed are compounds of Formula (IVA), or a salt thereof, and pharmaceutical formulations (pharmaceutical compositions) comprising those compounds, or a salt thereof: Formula (IVA), wherein 'R', 'R', &#x201c;R&#x201d;, &#x201c;R&#x201d;, &#x201c;R&#x201d;, are defined herein above, which compounds are believed suitable for use in positive modulation of the alpha 7 nicotinic acetylcholine receptor (&#x3b1;7 nAChR) receptors, for example, those found in the cerebral cortex and the hippocampus. Such compounds and pharmaceutical formulations are believed to be useful in treatment or management of neurodegenerative diseases, for example, Alzheimer's disease (AD), schizophrenia, and Parkinson's disease (PD), or movement disorders arising from use of certain medications used in the treatment or management of Parkinson's disease. 

Alpha-7 nicotinic acetylcholine receptor modulators and uses thereof

The present disclosure relates to compounds of formula I that are useful as modulators of &#x3b1;7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation 

Allosteric modulators of nicotinic acetylcholine receptors

The subject invention relates to novel P2Xreceptor antagonists that play a critical role in treating disease states associated with pain, in particular peripheral pain, inflammatory pain, or tissue injury pain that can be treated using a P2Xreceptor subunit modulator.

[object Object]

Growing community of inventors

Collegeville, PA, United States of America

Brendan M Crowley